期刊文献+

妇科恶性肿瘤腹膜后淋巴结切除术路径、要点及并发症防治 被引量:16

Route and main points of retroperitoneal lymph node dissection for gynecological malignancies and the prevention and treatment of complications
原文传递
导出
摘要 腹膜后(包括盆腔和腹主动脉旁)淋巴结切除在妇科恶性肿瘤的治疗中有重要的作用,常见的手术路径包括经腹腔路径和腹膜外路径。手术路径的选择取决于疾病治疗的整体方式、患者的特点和手术医师的技术特点。手术需要由有经验的妇科肿瘤医师实施。术中及术后近期并发症包括血管损伤、输尿管损伤、肠管损伤、神经损伤、围手术期感染,远期并发症最常见的是术后淋巴囊肿和下肢淋巴水肿。在淋巴囊肿和下肢淋巴水肿的预防中,应注意术后开放后腹膜,尽量避免使用引流管及合理使用能量器械等。 Retroperitoneal lymph node dissection,including pelvic and para-aortic lymphadenectomy,is of great importance in gynecological malignancies treatment.Lymphadenectomy can be performed via transperitoneal or extraperitoneal route.The surgical approach used for a lymphadenectomy procedure in gynecological oncology is typically determined by the best approach for the total procedure,patient characteristics and surgeon's experience.Surgery needs to be operated by an experienced gynecologic oncologist.The most frequent intraoperative and postoperative complication is vascular injury,followed by ureteral injury,bowel injury,neurologic injury,or perioperative infection.Late-postoperative complications consist mainly of symptomatic lymphatic lymphocyte(SPOL) and lower extremity lymphedema(LEL).Several techniques may decrease the incidence of SPOL and LEL.Thus,energy equipment should be rationally used during the procedure,the peritoneum should be left open and tube drains should be avoided.
作者 蒋芳 向阳
出处 《中国实用妇科与产科杂志》 CAS CSCD 北大核心 2017年第12期1233-1237,共5页 Chinese Journal of Practical Gynecology and Obstetrics
关键词 妇科肿瘤 盆腔淋巴结切除 腹主动脉旁淋巴结切除 并发症 gynecological malignancy pelvic lymphadenectomy paraaortic lymphadenectomy complication
  • 相关文献

参考文献2

二级参考文献15

  • 1Binder PS, PratJ, Mutch DG. The future role of molecular stag?ing in gynecologic cancer[J]. IntJ Gynaecol Obstet, 2015, 131 Suppl2: S127-131.
  • 2Romero I, Bast RC. Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy[J]. En?docrinology, 2012, 153(4): 1593-1602.
  • 3Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma[J]. Nature, 2011, 474(7353): 609-615.
  • 4Cancer Genome Atlas Research Network, Kandoth C, Schultz N, et al. Integrated genomic characterization of endometrial carcino?ma[J]. Nature, 2013,497(7447): 67-73.
  • 5Murali R, Soslow RA,Weigelt B. Classification of endometrial carcinoma: more than two types[J]. Lancet Oncol, 2014, 15(7): e268-278.
  • 6Iida M, Banno K, Yanokura M, et al. Candidate biomarkers for cervical cancer treatment: potential for clinical practice (Review)[J]. Mol Clin Oncol, 2014,2(5): 647-655.
  • 7Garces AH, Dias MS, Paulino E,et al. Treatment of ovarian can?cer beyond chemotherapy: are we hitting the target?[J]. Cancer Chemother Pharmacol, 2015,75(2): 221-234.
  • 8Burger RA, Brady MF, Bookman MA, et al. Incorporation of bev?acizumab in the primary treatment of ovarian cancer[J]. N EnglJ Med, 2011,365(26): 2473-2483.
  • 9Poveda AM, Selle F, Hilpert F, et al. Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: anal?ysis by chemotherapy cohort of the randomized phase III A URE?LIA trial[J].J Clin Oncol, 2015,33(32): 3836-3838.
  • 10Sessa C. Update on PARPI inhibitors in ovarian cancer[J]. Ann Oncol, 2011,22 (SuppI8):viii72-viii76.

共引文献14

同被引文献131

引证文献16

二级引证文献71

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部